{"id":"W3016397458","doi":"10.1111/bjd.19147","title":"Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Cilag; UCB Pharma; Sanofi Genzyme; Genentech; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Coherus Biosciences; Sun Pharma; Dermira; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Medac; Baxalta; Celgene; Pfizer; Biogen; Amgen; Meiji Seika Pharma; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Astellas Pharma US","keywords":"Ixekizumab; Placebo; Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00101759,0.0007290609,0.004224599,0.001047434,0.0002353693,0.00008925174,0.0005961776,0.0007189335,0.00001526482],"category_scores_gemma":[0.002761035,0.0006709135,0.0004216737,0.001011505,0.0003056669,0.0004205888,0.0002079581,0.001061794,0.00003316339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001054556,"about_ca_system_score_gemma":0.0004408467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001590467,"about_ca_topic_score_gemma":0.0003928964,"domain_scores_codex":[0.9925379,0.002568553,0.002777662,0.0007913931,0.0002814399,0.001043094],"domain_scores_gemma":[0.9914804,0.00581367,0.001635939,0.0003024645,0.0004644018,0.0003031182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8070915,0.01435014,0.1082527,0.0002675968,0.008642781,0.008635215,0.02421276,0.001099915,0.0006354129,0.00007957647,0.008266839,0.01846558],"study_design_scores_gemma":[0.9724145,0.001932115,0.01274272,0.0002440204,0.001378147,0.004793677,0.003793664,0.0000476603,0.001794695,0.00004645247,0.0006727017,0.0001396835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816152,0.01263276,0.0001995482,0.0001553984,0.0005447203,0.004327543,0.0001551321,0.00004135701,0.000328273],"genre_scores_gemma":[0.9967704,0.002169118,0.0001939779,0.0001998551,0.0001054213,0.0002498874,0.0001124104,0.00007583179,0.0001230806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.165323,"threshold_uncertainty_score":0.9995742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01241096948153409,"score_gpt":0.2384729632929913,"score_spread":0.2260619938114572,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}